Jean-Pierre Bassand discusses 'GARFIELD-AF registry: 2-year data' at the 2015 ESC congress in London.
1. Can you explain the objectives and rationale of the GARFIELD-AF registry?
2. What does the 2-year data tell us?
3. Are there any important regional differences within the data?
4. What side effects were reported and how severe were they?